Markets: CSL's antidote to excitement

The drug developer's chief has sought to dampen expectations for the company's 2014 performance despite continued demand for its products.

If the 2013 financial year was challenging, CSL chief executive Paul Perreault says 2014 will be even worse. The pharmaceutical company reported a 19 per cent increase in net profit to $US1.21 billion in 2013. CSL says 2014 net income growth will more than halve to 10 per cent.

Perreault may be just dampening expectations. But it points to nervousness about the health of the US economy and the uncertain regulatory environment facing many companies in and outside the pharmaceutical sector.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles